Wells Fargo’s Corbus Pharmaceuticals CRBP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $130K | Buy |
13,836
+13,792
| +31,345% | +$131K | ﹤0.01% | 5425 |
|
|
2026
Q1 | $410 | Hold |
44
| – | – | ﹤0.01% | 6416 |
|
|
2025
Q4 | $358 | Buy |
44
+43
| +4,300% | +$531 | ﹤0.01% | 6358 |
|
|
2025
Q3 | $15 | Sell |
1
-250
| -100% | -$2.38K | ﹤0.01% | 6758 |
|
|
2025
Q2 | $1.73K | Sell |
251
-6,397
| -96% | -$46.5K | ﹤0.01% | 6232 |
|
|
2025
Q1 | $35.3K | Buy |
6,648
+204
| +3% | +$1.8K | ﹤0.01% | 5503 |
|
|
2024
Q4 | $76K | Buy |
6,444
+2,195
| +52% | +$36.8K | ﹤0.01% | 5336 |
|
|
2024
Q3 | $87.7K | Sell |
4,249
-384
| -8% | -$19.7K | ﹤0.01% | 5094 |
|
|
2024
Q2 | $210K | Buy |
4,633
+3,552
| +329% | +$149K | ﹤0.01% | 4496 |
|
|
2024
Q1 | $42.4K | Buy |
1,081
+1,047
| +3,079% | +$25.8K | ﹤0.01% | 5324 |
|
|
2023
Q4 | $205 | Sell |
34
-581
| -94% | -$3.12K | ﹤0.01% | 6599 |
|
|
2023
Q3 | $4.14K | Buy |
615
+535
| +669% | +$3.7K | ﹤0.01% | 5984 |
|
|
2023
Q2 | $627 | Buy |
80
+1
| +1% | +$9 | ﹤0.01% | 6437 |
|
|
2023
Q1 | $575 | Sell |
79
-11,324
| -99% | -$49.5K | ﹤0.01% | 6517 |
|
|
2022
Q4 | $37.8K | Sell |
11,403
-160
| -1% | -$616 | ﹤0.01% | 4993 |
|
|
2022
Q3 | $57K | Sell |
11,563
-1
| -0% | -$7 | ﹤0.01% | 4892 |
|
|
2022
Q2 | $88K | Buy |
11,564
+2,637
| +30% | +$25.5K | ﹤0.01% | 4710 |
|
|
2022
Q1 | $142K | Buy |
8,927
+323
| +4% | +$4.28K | ﹤0.01% | 5155 |
|
|
2021
Q4 | $158K | Buy |
8,604
+235
| +3% | +$6.37K | ﹤0.01% | 5393 |
|
|
2021
Q3 | $257K | Buy |
8,369
+3,017
| +56% | +$119K | ﹤0.01% | 4994 |
|
|
2021
Q2 | $294K | Buy |
5,352
+1,313
| +33% | +$72.9K | ﹤0.01% | 4875 |
|
|
2021
Q1 | $238K | Buy |
4,039
+766
| +23% | +$50.4K | ﹤0.01% | 5081 |
|
|
2020
Q4 | $123K | Sell |
3,273
-3,192
| -49% | -$119K | ﹤0.01% | 5279 |
|
|
2020
Q3 | $349K | Buy |
6,465
+688
| +12% | +$125K | ﹤0.01% | 4615 |
|
|
2020
Q2 | $1.45M | Buy |
5,777
+1,481
| +34% | +$299K | ﹤0.01% | 3527 |
|
|
2020
Q1 | $675K | Buy |
4,296
+266
| +7% | +$45K | ﹤0.01% | 3805 |
|
|
2019
Q4 | $660K | Buy |
4,030
+57
| +1% | +$8.42K | ﹤0.01% | 4143 |
|
|
2019
Q3 | $580K | Buy |
3,973
+521
| +15% | +$90.7K | ﹤0.01% | 4263 |
|
|
2019
Q2 | $717K | Buy |
3,452
+228
| +7% | +$48.8K | ﹤0.01% | 4133 |
|
|
2019
Q1 | $672K | Buy |
3,224
+169
| +6% | +$37.3K | ﹤0.01% | 4162 |
|
|
2018
Q4 | $535K | Buy |
3,055
+219
| +8% | +$43.7K | ﹤0.01% | 4289 |
|
|
2018
Q3 | $643K | Sell |
2,836
-76
| -3% | -$12.3K | ﹤0.01% | 4270 |
|
|
2018
Q2 | $442K | Buy |
2,912
+221
| +8% | +$40.2K | ﹤0.01% | 4543 |
|
|
2018
Q1 | $493K | Buy |
2,691
+79
| +3% | +$17.7K | ﹤0.01% | 4395 |
|
|
2017
Q4 | $556K | Buy |
2,612
+849
| +48% | +$182K | ﹤0.01% | 4317 |
|
|
2017
Q3 | $379K | Buy |
1,763
+1,673
| +1,859% | +$327K | ﹤0.01% | 4515 |
|
|
2017
Q2 | $17K | Hold |
90
| – | – | ﹤0.01% | 5657 |
|
|
2017
Q1 | $22K | Buy |
90
+40
| +80% | +$9.82K | ﹤0.01% | 5686 |
|
|
2016
Q4 | $13K | Sell |
50
-67
| -57% | -$15.4K | ﹤0.01% | 5730 |
|
|
2016
Q3 | $24K | Buy |
+117
| New | +$14.6K | ﹤0.01% | 5548 |
|
Other funds holding CRBP
CAM
O
JHC
PM
SCM
ACM
Wells Fargo's CRBP Position: Q2 2026 in Review
Wells Fargo increased its Corbus Pharmaceuticals (CRBP) stake by 31,345% in Q2 2026, buying an estimated $131K and bringing the position to 13,836 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #5425.
Wells Fargo first reported a position in CRBP in Q3 2016 and has held it in 40 quarters since. The position peaked at $1.45M in Q2 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.
- Wells Fargo held 13,836 shares of Corbus Pharmaceuticals worth $130K as of Q2 2026.
- Wells Fargo bought 13,792 Corbus Pharmaceuticals shares in Q2 2026, an estimated $131K.
- Corbus Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5425 holding.
- Wells Fargo first reported a position in Corbus Pharmaceuticals in Q3 2016 and has held it in 40 quarters since.
- Wells Fargo's Corbus Pharmaceuticals position peaked at $1.45M in Q2 2020.
- 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.